SG11202112256SA - Stabilized formulations containing anti-angptl3 antibodies - Google Patents

Stabilized formulations containing anti-angptl3 antibodies

Info

Publication number
SG11202112256SA
SG11202112256SA SG11202112256SA SG11202112256SA SG11202112256SA SG 11202112256S A SG11202112256S A SG 11202112256SA SG 11202112256S A SG11202112256S A SG 11202112256SA SG 11202112256S A SG11202112256S A SG 11202112256SA SG 11202112256S A SG11202112256S A SG 11202112256SA
Authority
SG
Singapore
Prior art keywords
antibody
pharmaceutical formulation
formulation
concentration
seq
Prior art date
Application number
SG11202112256SA
Other languages
English (en)
Inventor
Dingjiang Liu
Andria Skinner
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202112256SA publication Critical patent/SG11202112256SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11202112256SA 2019-05-24 2020-05-24 Stabilized formulations containing anti-angptl3 antibodies SG11202112256SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962852643P 2019-05-24 2019-05-24
PCT/US2020/034438 WO2020243031A1 (en) 2019-05-24 2020-05-24 Stabilized formulations containing anti-angptl3 antibodies

Publications (1)

Publication Number Publication Date
SG11202112256SA true SG11202112256SA (en) 2021-12-30

Family

ID=72179136

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112256SA SG11202112256SA (en) 2019-05-24 2020-05-24 Stabilized formulations containing anti-angptl3 antibodies

Country Status (17)

Country Link
US (1) US12559551B2 (https=)
EP (1) EP3976647A1 (https=)
JP (1) JP7783051B2 (https=)
KR (1) KR20220011727A (https=)
CN (1) CN114007647A (https=)
AU (1) AU2020282956A1 (https=)
BR (1) BR112021023501A2 (https=)
CA (1) CA3139333A1 (https=)
CL (1) CL2021003026A1 (https=)
CO (1) CO2021016183A2 (https=)
EA (1) EA202193240A1 (https=)
IL (1) IL288153A (https=)
MA (1) MA56049A (https=)
MX (1) MX2021014332A (https=)
PH (1) PH12021552788A1 (https=)
SG (1) SG11202112256SA (https=)
WO (1) WO2020243031A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN107635527B (zh) 2015-03-10 2021-04-23 里珍纳龙药品有限公司 无菌刺穿系统和方法
JP7541810B2 (ja) 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
KR102540409B1 (ko) 2017-05-05 2023-06-09 리제너론 파아마슈티컬스, 인크. 자동 주사기
WO2022191550A1 (ko) * 2021-03-09 2022-09-15 (주)지아이이노베이션 ＩｇＥ Ｆｃ 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형
TW202320847A (zh) * 2021-07-21 2023-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種抗ａｎｇｐｔｌ３抗體或其抗原結合片段的醫藥組成物及其用途
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
IL313191A (en) 2021-12-22 2024-07-01 Regeneron Pharma Treatment of kidney diseases using angiopoietin-like inhibitors 3
WO2023213779A1 (en) 2022-05-02 2023-11-09 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
JP2025537256A (ja) 2022-11-10 2025-11-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンジオポエチン様３（ａｎｇｐｔｌ３）阻害剤と溶質担体ファミリー５メンバー２（ｓｌｃ５ａ２）阻害剤の組み合わせによる腎疾患の治療
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
WO2026051789A1 (zh) * 2024-09-03 2026-03-12 四川科伦博泰生物医药股份有限公司 Pcsk9和angptl3的结合蛋白及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
AU781295B2 (en) 1999-02-12 2005-05-12 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
NZ527408A (en) 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
JP5105696B2 (ja) 2001-11-16 2012-12-26 ジェネンテック， インコーポレイテッド アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
AU2006223579A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
PL2121751T3 (pl) 2006-12-08 2017-07-31 Lexicon Pharmaceuticals, Inc. Przeciwciała monoklonalne przeciwko ANGPTL3
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
JP5711671B2 (ja) 2009-02-23 2015-05-07 ナノルクス、インコーポレイテッドＮａｎｏｒｘ，Ｉｎｃ． ポリコサノールナノ粒子
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
AU2010273570B2 (en) 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
US8653047B2 (en) 2010-01-08 2014-02-18 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
ES2923573T3 (es) 2011-06-21 2022-09-28 Alnylam Pharmaceuticals Inc Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
US20150239970A1 (en) 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
EP2996706B1 (en) 2013-03-14 2019-07-31 UAB Research Foundation Apolipoprotein mimetics and uses thereof
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
CN111394355A (zh) 2013-12-24 2020-07-10 Ionis制药公司 促血管生成素样3表达的调节
PT3137605T (pt) 2014-05-01 2020-12-18 Ionis Pharmaceuticals Inc Composições e métodos para modulação da expressão de angiopoietina de tipo 3
RU2723018C2 (ru) 2014-07-16 2020-06-08 Санофи Байотекнолоджи Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию
PL3169353T3 (pl) 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
EP3822287A1 (en) 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
PL3416684T3 (pl) 2016-02-17 2023-11-06 Regeneron Pharmaceuticals, Inc. Sposoby leczenia lub profilaktyki miażdżycy tętnic przez podawanie inhibitora angptl3
JP7541810B2 (ja) 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
KR20180132843A (ko) 2016-04-08 2018-12-12 리제너론 파아마슈티컬스, 인크. Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법
IL293308B2 (en) 2016-04-28 2024-12-01 Regeneron Pharma Methods for treating patients with familial hypercholesterolemia
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
AU2021320417A1 (en) 2020-08-07 2023-03-30 Regeneron Pharmaceuticals, Inc. Methods for treating refractory hypercholesterolemia involving an ANGPTL3 inhibitor

Also Published As

Publication number Publication date
MX2021014332A (es) 2022-04-06
MA56049A (fr) 2022-04-06
CO2021016183A2 (es) 2021-12-10
EA202193240A1 (ru) 2022-03-14
JP7783051B2 (ja) 2025-12-09
IL288153A (en) 2022-01-01
KR20220011727A (ko) 2022-01-28
JP2022532927A (ja) 2022-07-20
PH12021552788A1 (en) 2022-09-28
CN114007647A (zh) 2022-02-01
CA3139333A1 (en) 2020-12-03
EP3976647A1 (en) 2022-04-06
US20200369760A1 (en) 2020-11-26
BR112021023501A2 (pt) 2022-01-18
WO2020243031A1 (en) 2020-12-03
AU2020282956A1 (en) 2022-01-27
CL2021003026A1 (es) 2022-06-24
US12559551B2 (en) 2026-02-24

Similar Documents

Publication Publication Date Title
US12559551B2 (en) Stabilized formulations containing anti-ANGPTL3 antibodies
JP6456470B2 (ja) 抗ｐｃｓｋ９抗体を含む安定化製剤
KR102667484B1 (ko) 안정한 항체 제형
CA3035252C (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
EP3354280B1 (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JP7674369B2 (ja) 安定な抗体製剤
JP6144758B2 (ja) 抗Ｄｌｌ４抗体を含有する安定化製剤
WO2025096478A1 (en) Stable antibody formulation comprising fianlimab
TWI498121B (zh) 含有抗－介白素－４受體（ｉｌ－４ｒ）抗體之安定化配製物
EA048605B1 (ru) Стабилизированные составы, содержащие анти-angptl3-антитела
WO2025226695A1 (en) Stable antibody formulation
HK40096835A (en) Stabilized formulations containing anti-pcsk9 antibodies
HK40039744A (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1232793A1 (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies